Health
Pages
0
Vioxx: Adding new meaning to "drug trials"
Nov 1, 2005
Jurors are expected to begin deliberations Tuesday in the second liability trial involving Merck's arthritis drug Vioxx. Helen Palmer reviews the case and looks at what's at stake for Merck.
0
Novartis buys Chiron
Oct 31, 2005
Pharmaceutical companies have been working to come up with vaccines and drugs to treat the bird flu. But it may a more pedestrian influenza that are guiding their business decisions. Alisa Roth has more.
0
Generic Drugs
Oct 31, 2005
The American health care system could save up to $20 billion if patients were prescribed generic rather than brand-name drugs. But as Helen Palmer reports, Big Pharma says not all drugs are equal.
0
NIH Disclosure
Oct 31, 2005
Monday is the deadline for employees and researchers at the National Institutes of Health to disclose all stock holdings to prevent potential conflicts of interest. Rachel Dornhelm reports.
0
Saving us from ourselves?
Oct 27, 2005
Pharmaceutical company Roche is temporarily suspending shipments of Tamiflu to the United States to prevent stockpiling of the drug and make sure there's enough for later. Helen Palmer reports.
0
Junior insomniacs?
Oct 26, 2005
A new study finds that youth under 18 are the fastest growing segment of the sleeping pill market. As Helen Palmer reports, Big Pharma is encouraging the trend.
0
Performing surgery on Medicare and Medicaid
Oct 25, 2005
Congress is making a big push this week to come up with spending cuts to help lower the federal budget deficit. In the spotlight today were proposals to trim Medicare and Medicaid. John Dimsdale reports from Washington.
0
Say what you will about WalMart...
Oct 24, 2005
...but the country's biggest employer knows when to beat a strategic retreat. Today it will introduce a cheaper health plan for workers. Helen Palmer reports that it's not a simple story, though.
0
Supply, demand, and Tamiflu
Oct 21, 2005
Everyone wants Tamiflu made by Swiss pharmaceutical company Roche, but there's not enough of it. Now Roche say it will meet with generic drug companies. Host Kai Ryssdal talks to Stephen Beard in London.
0
A diabetes treatment: worth the risk?
Oct 20, 2005
Merck and Bristol Myers-Squibb have developed a new diabetes drug, Pargluva. Last month, an FDA panel recommended approval. But it seems it can double the risk of heart attacks and strokes. Cheryl Glaser has more.
Pages
Buzzworthy
Recent comments on our stories..
Three life rules from Donald Rumsfeld
Journalism: Practiced. Excellent interview. Thank you.
Annapolis57 | May 17, 2013 Three life rules from Donald Rumsfeld
Donald Rumsfeld's interview on Marketplace today was absolutely unbelievable. Really. Is one of his rules not to believe your own spin? I...
jgrothues | May 16, 2013 Three life rules from Donald Rumsfeld
Ryssdal's interview with Rumsfeld was breathtakingly inappropriate. "Marketplace?" If Ryssdal wants to promote his obvious biases...
rcd43 | May 16, 2013 How World Finance makes a killing lending on the installment (loan) plan
There is something fundamentally wrong with predatory lending businesses, whether they are pay day loans or installment contracts. The business...
entropyman | May 15, 2013
